title: Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization.
abstract: A combination AIDS vaccine approach consisting of priming with adenovirus-HIV-1MN gp160 recombinants followed by boosting with HIV-1SF2 gp120 was evaluated in chimpanzees. Long-lasting protection, requiring only three immunizations, was achieved against a low-dose challenge with the SF2 strain of HIV-1 and a subsequent high-dose SF2 challenge administered 1 year later without an intervening boost. Notably, neutralizing antibody responses against both clinical and laboratory isolates developed in three chimpanzees and persisted until the time of high-dose challenge. The possibility that cytotoxic T-lymphocytes contribute to low-dose protection of a chimpanzee lacking neutralizing antibodies is suggested. Our results validate the live vector priming/subunit booster approach and should stimulate interest in assessing this combination vaccine approach in humans.
authors.affiliation: Wyeth-Ayerst Research, Radnor, PA 19087, USA.
authors.forename: M D
authors.initials: MD
authors.lastname: Lubeck
authors.forename: R
authors.initials: R
authors.lastname: Natuk
authors.forename: M
authors.initials: M
authors.lastname: Myagkikh
authors.forename: N
authors.initials: N
authors.lastname: Kalyan
authors.forename: K
authors.initials: K
authors.lastname: Aldrich
authors.forename: F
authors.initials: F
authors.lastname: Sinangil
authors.forename: S
authors.initials: S
authors.lastname: Alipanah
authors.forename: S C
authors.initials: SC
authors.lastname: Murthy
authors.forename: P K
authors.initials: PK
authors.lastname: Chanda
authors.forename: S M
authors.initials: SM
authors.lastname: Nigida
authors.forename: P D
authors.initials: PD
authors.lastname: Markham
authors.forename: S
authors.initials: S
authors.lastname: Zolla-Pazner
authors.forename: K
authors.initials: K
authors.lastname: Steimer
authors.forename: M
authors.initials: M
authors.lastname: Wade
authors.forename: M S
authors.initials: MS
authors.lastname: Reitz
authors.forename: L O
authors.initials: LO
authors.lastname: Arthur
authors.forename: S
authors.initials: S
authors.lastname: Mizutani
authors.forename: A
authors.initials: A
authors.lastname: Davis
authors.forename: P P
authors.initials: PP
authors.lastname: Hung
authors.forename: R C
authors.initials: RC
authors.lastname: Gallo
authors.forename: J
authors.initials: J
authors.lastname: Eichberg
authors.forename: M
authors.initials: M
authors.lastname: Robert-Guroff
mesh_terms: D000256:Adenoviridae / Q000276:immunology*; D000818:Animals; D005260:Female; D015699:HIV Envelope Protein gp120 / Q000276:immunology*; D019302:HIV Envelope Protein gp160 / Q000276:immunology*; D015658:HIV Infections / Q000276:immunology / Q000517:prevention & control; D015497:HIV-1 / Q000472:pathogenicity*; D002679:Pan troglodytes; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000502:physiology; D014611:Vaccination / Q000379:methods*; D014612:Vaccines / Q000008:administration & dosage
chemical_list: D015699:HIV Envelope Protein gp120; D019302:HIV Envelope Protein gp160; D011993:Recombinant Fusion Proteins; D014612:Vaccines